Effective as of August 13, 2018, Maximilian Scheder-Bieschin retired as the Chief Financial Officer and Secretary of Ekso Bionics Holdings, Inc. Mr. Scheder-Bieschin will remain an employee of the company through the end of August. After that, Mr. Scheder-Bieschin will serve as a consultant to the company until December 31, 2018, pursuant to the terms of a Transition Services Agreement dated May 7, 2018 by and between the company and Mr. Scheder-Bieschin, and will continue to assist the company's new Chief Financial Officer, Mr. Jack Glenn, in the transition process. On August 1, 2018, John (Jack) Glenn accepted an offer of employment from the company to serve as the new Chief Financial Officer of the company, effective August 13, 2018.

Mr. Glenn will also serve as the company's new Secretary. Mr. Glenn brings 25 years of financial leadership experience in public and private companies in the life sciences industry. From March 2018 until now, Mr. Glenn has been working as a consultant to biotechnology and medical device companies.

In such role, Mr. Glenn has been advising senior management of such companies in respect of financial, accounting and operational matters, including fundraising, development of internal controls and processes and budgeting. From 2016 to 2017, Mr. Glenn served as the Chief Financial Officer of Sonendo Inc.